Person: ÖZEN, AHMET OĞUZHAN
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
ÖZEN
First Name
AHMET OĞUZHAN
Name
8 results
Search Results
Now showing 1 - 8 of 8
Publication Metadata only CHAPLE disease and non-CHAPLE protein losing enteropathies: natural history and immune characteristics(2021-08-01) SELÇUK, MERVE; BARIŞ, SAFA; ÖZEN, AHMET OĞUZHAN; ÖĞÜLÜR, İSMAİL; AYDINER, ELİF; Selcuk M., Sefer A. P., Baser D., Ogulur I., Eltan S. B., Dursun E., Kocamis B., Kasap N., BARIŞ S., AYDINER E., et al.Publication Metadata only The epithelial barrier damaging effects of professional dishwasher rinse aid on Caco-2 gastrointestinal epithelial cells(2021-08-01) ÖZEN, AHMET OĞUZHAN; Ogulur I., Ruckert B., Ozen A. O., Akdis C. A.Publication Metadata only Clinical, immunological, molecular and therapeutic findings in monogenic immune dysregulation diseases: Middle East and North Africa registry(2022-11-01) BARIŞ, SAFA; ÖZEN, AHMET OĞUZHAN; Jamee M., Azizi G., BARIŞ S., Karakoc-Aydiner E., ÖZEN A. O. , KILIÇ GÜLTEKİN S. Ş. , KÖSE H., Chavoshzadeh Z., Mahdaviani S. A. , Momen T., et al.© 2022Monogenic immune dysregulation diseases (MIDD) are caused by defective immunotolerance. This study was designed to increase knowledge on the prevalence and spectrum of MIDDs, genetic patterns, and outcomes in Middle East and North Africa (MENA). MIDD patients from 11 MENA countries (Iran, Turkey, Kuwait, Oman, Algeria, Egypt, United Arab Emirates, Tunisia, Jordan, Qatar, and Azerbaijan) were retrospectively evaluated. 343 MIDD patients (58% males and 42% female) at a median (IQR) age of 101 (42–192) months were enrolled. The most common defective genes were LRBA (23.9%), LYST (8.2%), and RAB27A (7.9%). The most prevalent initial and overall manifestations were infections (32.2% and 75.1%), autoimmunity (18.6% and 41%), and organomegaly (13.3% and 53.8%), respectively. Treatments included immunoglobulin replacement therapy (53%), hematopoietic stem cell transplantation (HSCT) (14.3%), immunosuppressives (36.7%), and surgery (3.5%). Twenty-nine (59.2%) patients survived HSCT. Along with infectious complications, autoimmunity and organomegaly may be the initial or predominant manifestations of MIDD.Publication Metadata only Reversal clinical and immunological effects of abatacept in patients with LRBA and CTLA4 deficiencies(2021-08-01) BARIŞ, SAFA; ÖZEN, AHMET OĞUZHAN; AYDINER, ELİF; BARIŞ S., Babayeva R., Catak M. C., Baser D., Eltan S. B., Akgun G., Bulutoglu A., Karakus I. S., Karadag S. I. K., Hancioglu G., et al.Publication Metadata only Single cell sequencing of peripheral mononuclear cells reveals CHAPLE-specific distinct signaling pathways(2021-08-01) ÖZEN, AHMET OĞUZHAN; BARIŞ, SAFA; AYDINER, ELİF; Ogulur I., Kim J., Ruckert B., Pat Y., AYDINER E., BARIŞ S., Ozen A. O., Akdis C. A.Publication Metadata only Adverse covid outcomes in youngsters with immune deficiencies; inequality exists between subclasses(2021-08-01) KOLUKISA, BURCU; KEPENEKLİ KADAYİFCİ, EDA; ÖZEN, AHMET OĞUZHAN; BARIŞ, SAFA; AYDINER, ELİF; AYDINER E., Eltan S. B., Babayeva R., Aydiner O., KEPENEKLİ KADAYİFCİ E., KOLUKISA B., Sefer A. P., Gungoren E. Y., Karabiber E., YÜCEL E., et al.Publication Metadata only Autoinflammatory manifestations as a result of an elevated type I IFN signature in a case of NEMO deficiency(2021-08-01) BARIŞ, SAFA; ÖZEN, AHMET OĞUZHAN; AYDINER, ELİF; Yilmaz N. S., Eltan S. B., KAYAOĞLU B., Geckin B., Sozeri B., KIYKIM A., AYDINER E., BARIŞ S., Ozen A. O., Gursel I., et al.Publication Metadata only Genomic investigation into early onset protein-losing enteropathies: therapeutic implications and insights into clusters of shared pathomechanisms(2021-08-01) BARIŞ, SAFA; ÖZEN, AHMET OĞUZHAN; AYDINER, ELİF; Sefer A. P., AYDINER E., Urganci N., Kiykim E., Baysoy G., Fisher M., Ertem D., Bayrak A., VAROL F. İ., İŞLEK A., et al.